Pharmacological evaluation of SN79, a sigma (σ) receptor ligand, against methamphetamine-induced neurotoxicity in vivo

European Neuropsychopharmacology

Volumn 23, Issue 8, 2013, Pages 960-971

  Kaushal, Nidhi ^a   Seminerio, Michael J ^a   Robson, Matthew J ^a   McCurdy, Christopher R ^b   Matsumoto, Rae R ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Dopamine; Hyperthermia; Methamphetamine; Neurotoxicity; Serotonin; Sigma receptors

Indexed keywords

6 ACETYL 3 [4 [4 (4 FLOROPHENYL)PIPERAZIN 1 YL]BUTYL]BENZO[D]OXAZOL 2(3H) ONE; DI O TOLYLGUANIDINE; GUANIDINE DERIVATIVE; METHAMPHETAMINE; SEROTONIN TRANSPORTER; SIGMA RECEPTOR LIGAND; SN 79; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BRAIN; CONTROLLED STUDY; DEPLETION; DRUG SYNTHESIS; IN VIVO STUDY; LETHALITY; MALE; METHAMPHETAMINE INDUCED HYPERTHERMIA; METHAMPHETAMINE INDUCED NEUROTOXICITY; MODULATION; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

DOPAMINE; HYPERTHERMIA; METHAMPHETAMINE; NEUROTOXICITY; SEROTONIN; SIGMA RECEPTORS;

ANIMALS; BENZOXAZOLES; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DRUG SYNERGISM; FEVER; GUANIDINES; MALE; METHAMPHETAMINE; MICE; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; PIPERAZINES; RANDOM ALLOCATION; RECEPTORS, SIGMA; SEROTONIN; SEROTONIN ANTAGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84881660940     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.08.005     Document Type: Article

References (36)

1. Baldwin H.A., Colado M.I., Murray T.K., Souza R.J., Grren A.R. Striatal dopamine release in vivo following neurotoxic doses of methamphetamine and effect of the neuroprotective drugs, chlormethiazole and dizocilpine. Br. J. Pharmacol. 1993, 108:590-596.
2. Bowyer J.F., Davis D.L., Schmued L., Broening H.W., Newport G.D., Slikker W., Holson R.R. Further studies on the role of hyperthermia in methamphetamine neurotoxicity. J. Pharmacol. Exp. Ther. 1994, 268:1571-1580.
3. Brunswick D.J., Benmansour S., Tejani-Butt S.M., Hauptmann M. Effects of high-dose methamphetamine on monoamine uptake sites in rat brain measured by quantitative autoradiography. Synapse 1992, 11:287-293.
4. Callaghan R.C., Cunningham J.K., Sykes J., Kish S.J. Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend. 2012, 120:35-40.
5. Cappon G.D., Pu C., Vorhees C.V. Time-course of methamphetamine-induced neurotoxicity in rat caudate-putamen after single-dose treatment. Brain Res. 2000, 863:106-111.
6. Cruickshank C.C., Dyer K.R. A review of the clinical pharmacology of methamphetamine. Addiction 2009, 104:1085-1099.
7. Fleckenstein A.E., Wilkins D.G., Gibb J.W., Hanson G.R. Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration. J. Pharmacol. Exp. Ther. 1997, 283:281-285.
8. Fukumura M., Cappon G.D., Pu C., Broening H.W., Voorhees C.V. A single dose model of methamphetamine-induced neurotoxicity in rats: effects on neostriatal monoamines and glial fibrillary acidic protein. Brain Res. 1998, 806:1-7.
9. Gough B., Imam S.Z., Blough D., Slikker W., Ali S.F. Comparative effect of substituted amphetamines (PMA, MDMA, and METH) on monoamines in rat caudate: a microdialysis study. Ann. N.Y. Acad. Sci. 2002, 965:410-420.
10. Guitart X., Codony X., Monroy X. Sigma receptors: biology and therapeutic potential. Psychopharmacology 2004, 174:301-319.
11. Hart C.L., Marvin C.B., Silver R., Smith E.E. Is cognitive functioning impaired in methamphetamine users? A critical review. Neuropsychopharmacology 2012, 37:586-608.
12. Hirata H., Ladenheim B., Rothman R.B., Epstein C., Cadet J.L. Methamphetamine-induced serotonin neurotoxicity is mediated by superoxide radicals. Brain Res. 1995, 677:345-347.
13. Kaushal N., Robson M.J., Vinnakota H., Narayanan S., Avery B.A., McCurdy C.R., Matsumoto R.R. Synthesis and pharmacological evaluation of 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2-(3H)-one (SN79), a cocaine antagonist, in rodents. AAPS J. 2011, 13:336-346.
14. Kaushal N., Seminerio M.J., Shaikh J., Medina M.A., Mesangeau C., Wilson L.L., McCurdy C.R., Matsumoto R.R. CM156, a high affinity sigma ligand, attenuates the stimulant and neurotoxic effects of methamphetamine in mice. Neuropharmacology 2011, 61:992-1000.
15. Kaushal N., Elliott M., Robson M.J., Iyer A.K., Rojanasakul Y., Coop A., Matsumoto R.R. AC927, a sigma receptor ligands, blocks methamphetamine-induced release of dopamine and generation of reactive oxygen species in NG108-15 cells. Mol. Pharmacol. 2012, 81:299-308.
16. Kaushal N., Matsumoto R.R. Role of sigma receptors in methamphetamine-induced neurotoxicity. Curr. Neuropharmacol. 2011, 9:54-57.
17. Kaushal, N., McCurdy, C.R., Matsumoto, R.R., 2011c. SN79 Attenuates the Neurotoxic Effect of Methamphetamine: In Vivo and in Vitro Studies. Society for Neuroscience meeting 2011 Program 367.03.
18. Kita T., Matsunari Y., Saraya T., Shimada K., O'Hara K., Kubo K., Wagner G.C., Nakashima T. Methamphetamine-induced striatal dopamine release, behavior changes and neurotoxicity in BALB/c mice. Int. J. Dev. Neurosci. 2000, 18:521-530.
19. Kiyatkin E.A., Brown P.L., Sharma H.S. Brain edema and breakdown of the blood-brain barrier during methamphetamine intoxication: critical role of brain hyperthermia. Eur. J. Neurosci. 2007, 26:1242-1253.
20. 3H]cyanoimipramine autoradiography. Brain Res. 1989, 505:123-129.
21. Krasnova I.N., Cadet J.L. Methamphetamine toxicity and messengers of death. Brain Res. Rev. 2009, 60:379-407.
22. Kuczenski R., Segal D.S., Cho A.K., Melaga W. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J. Neurosci. 1995, 15:1308-1317.
23. 1 receptor prodice anti-cocaine effects in mice. Eur. J. Pharmacol. 2001, 419:163-174.
24. Matsumoto R.R., Shaikh J., Wilson L.L., Vedam S., Coop A. Attenuation of methampehtamine-induced effects through the antagonism of sigma (σ) receptors: Evidence from in vivo and in vitro studies. Eur. J. Pharmacol. 2008, 18:871-881.
25. McLean S., Weber E. Autoradiographic visualization of haloperidol-sensitive sigma receptors in guinea-pig brain. Neuroscience 1988, 25:259-269.
26. 1 receptors in Parkinson's disease. Acta Neurol. Scand. 2005, 112:103-107.
27. Nguyen E.C., McCracken K.A., Pouw B., Matsumoto R.R. Involvement of sigma receptors in the actions of methamphetamine: receptor binding and behavioral studies. Neuropharmacology 2005, 49:638-645.
28. Numachi Y., Ohara A., Yamashita M., Fukushima S., Kobayashi H., Hata H., Watanabe H., Hall F.S., Lesch K.P., Murphy D.L., Uhl G.R., Sora I. Methamphetamine-induced hyperthermia and lethal toxicity: role of the dopmaine and serotonin transporters. Eur. J. Pharmacol. 2007, 572:120-128.
29. Ricaurte G.A., Schuster C.R., Seiden L.S. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res. 1980, 193:153-163.
30. Robson M.J., Noorbakhsh B., Seminerio M.J., Matsumoto R.R. Sigma-1 receptors: potential targets for the treatment of substance abuse. Curr. Pharm. Des. 2012, 18:902-919.
31. Scott J.C., Woods S.P., Matt G.E., Meyer R.A., Heaton R.K., Atkinson J.H., Grant I. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychological. Rev. 2007, 17:275-297.
32. Seiden L.S., Commins D.L., Vosmer G., Axt K., Marek G. Neurotoxicity in dopamine and 5-hydroxytryptamine terminal fields: a regional analysis in nigrostriatal and mesolimbic projections. Ann. N.Y. Acad. Sci. 1988, 537:161-172.
33. Sharma H.S., Sjoquist P.O., Ali S.F. Drugs of abuse-induced hyperthermia, blood-brain barrier dysfunction and neurotoxicity: neuroprotective effects of a new antioxidant compound H-290/51. Curr. Pharm. Des. 2007, 13:1903-1923.
34. van Waarde A., Rybczynska A.A., Ramakrishnan N., Ishiwata K., Elsinga P.H., Dierckx R.A. Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands. Curr. Pharm. Des. 2010, 16:3519-3537.
35. Walker J.M., Bowen W.D., Walker F.O., Matsumoto R.R., De Costa B.R., Rice K.C. Sigma receptors: biology and function. Pharmacological. Rev. 1990, 42:355-402.
36. Xie T., McCann U.D., Kim S., Yuan J., Ricaurte G.A. Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity. J. Neurosci. 2000, 20:7838-7845.